-
Signature
-
/s/ Jonathan Golightly, attorney-in-fact
-
Issuer symbol
-
RXRX
-
Transactions as of
-
02 Dec 2025
-
Transactions value $
-
-$961,400
-
Form type
-
4
-
Filing time
-
04 Dec 2025, 16:51:31 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Borgeson Blake |
Director |
C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY |
/s/ Jonathan Golightly, attorney-in-fact |
04 Dec 2025 |
0001856094 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RXRX |
Class A Common Stock |
Sale |
-$961K |
-220K |
-3.1% |
$4.37 |
6.87M |
02 Dec 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: